We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+9.6%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$72.7B
AUM Growth
+$7.54B
(+12%)
Cap. Flow
-$3.34B
Cap. Flow
% of AUM
-4.6%
Top 10 Holdings %
Top 10 Hldgs %
23.55%
Holding
2,585
New
253
Increased
940
Reduced
728
Closed
298
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Crown Castle
CCI
|
+$536M |
| 2 |
Procter & Gamble
PG
|
+$358M |
| 3 |
CSX Corp
CSX
|
+$303M |
| 4 |
NVIDIA
NVDA
|
+$186M |
| 5 |
Eli Lilly
LLY
|
+$185M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$370M |
| 2 |
American Electric Power
AEP
|
+$338M |
| 3 |
Alibaba
BABA
|
+$322M |
| 4 |
Prologis
PLD
|
+$307M |
| 5 |
HEICO Corp
HEI
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.03% |
| 2 | Financials | 13.75% |
| 3 | Industrials | 12.1% |
| 4 | Healthcare | 10.45% |
| 5 | Consumer Discretionary | 7.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Brown & Brown
BRO
$23.8B
| $21K | ﹤0.01% |
196
-3,005
| -94% | -$338K |
|
1902
Equity Residential
EQR
$25.4B
| $21K | ﹤0.01% |
323
-10
| -3% | -$687 |
|
1903
Iron Mountain
IRM
$37.3B
| $21K | ﹤0.01% |
210
-283
| -57% | -$26.7K |
|
1904
Krystal Biotech
KRYS
$9.61B
| $21K | ﹤0.01% |
155
-249
| -62% | -$36.6K |
|
1905
Ultragenyx Pharmaceutical
RARE
$2.54B
| $21K | ﹤0.01% |
588
-33,455
| -98% | -$1.21M |
|
1906
Spectrum Brands
SPB
$2.09B
| $21K | ﹤0.01% |
411
-35,897
| -99% | -$2.14M |
|
1907
Douglas Elliman
DOUG
$160M
| $20K | ﹤0.01% |
8,946
+1,668
| +23% | +$3.56K |
|
1908
Dow Inc
DOW
$21.9B
| $20K | ﹤0.01% |
759
-5,963
| -89% | -$173K |
|
|
FSP
1909
Franklin Street Properties
FSP
$48.4M
| $20K | ﹤0.01% |
12,525
| – | – |
|
|
GNTY
1910
DELISTED
Guaranty Bancshares
GNTY
| $20K | ﹤0.01% |
+483
| New | +$19.5K |
|
1911
Granite Ridge Resources
GRNT
$629M
| $20K | ﹤0.01% |
3,200
-117,932
| -97% | -$650K |
|
1912
Sibanye-Stillwater
SBSW
$6.77B
| $20K | ﹤0.01% |
2,864
| – | – |
|
|
FOLD
1913
DELISTED
Amicus Therapeutics
FOLD
| $19K | ﹤0.01% |
3,488
-7,326
| -68% | -$47.3K |
|
1914
Invitation Homes
INVH
$18.1B
| $19K | ﹤0.01% |
597
-18
| -3% | -$604 |
|
1915
Ardelyx
ARDX
$1.24B
| $18K | ﹤0.01% |
4,655
-11,698
| -72% | -$48.3K |
|
1916
Geron
GERN
$860M
| $18K | ﹤0.01% |
13,123
-39,930
| -75% | -$56.6K |
|
1917
Immatics
IMTX
$1.28B
| $18K | ﹤0.01% |
3,350
-3,489
| -51% | -$17.3K |
|
1918
Kura Oncology
KURA
$841M
| $18K | ﹤0.01% |
3,234
-8,517
| -72% | -$52.2K |
|
1919
Agios Pharmaceuticals
AGIO
$1.89B
| $17K | ﹤0.01% |
534
-2,124
| -80% | -$64.4K |
|
|
APLS
1920
DELISTED
Apellis Pharmaceuticals
APLS
| $17K | ﹤0.01% |
1,024
-2,529
| -71% | -$46.8K |
|
1921
Vericel Corp
VCEL
$2.37B
| $17K | ﹤0.01% |
410
-29,239
| -99% | -$1.22M |
|
|
EXE
1922
Expand Energy Corp
EXE
$21.5B
| $17K | ﹤0.01% |
150
-1,105
| -88% | -$123K |
|
1923
Bank7 Corp
BSVN
$486M
| $16K | ﹤0.01% |
+402
| New | +$15.3K |
|
1924
Acme United Corp
ACU
$212M
| $15K | ﹤0.01% |
+365
| New | +$14.4K |
|
1925
GDS Holdings
GDS
$6.69B
| $15K | ﹤0.01% |
504
| – | – |
|
Similar funds
QCM
Lazard Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Lazard Asset Management held 2,585 positions worth $72.7B, up 12% from $65.1B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $3.34B in Q2 2025, closing 298 positions and reducing 728 holdings. Its most notable exit was Eastman Chemical, an estimated $13.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Financials and Industrials.
Against the trend, Lazard Asset Management opened a new position in Arcos Dorados Holdings worth $117M.
- Lazard Asset Management's largest Q2 2025 buy was Arcos Dorados Holdings: 14,873,278 shares worth $117M.
- Lazard Asset Management added most to Crown Castle in Q2 2025, an estimated $536M increase.
- Lazard Asset Management's biggest Q2 2025 reduction was NetEase, cutting an estimated $370M.
- Lazard Asset Management fully exited Eastman Chemical in Q2 2025, selling an estimated $13.1M.
- Lazard Asset Management's ten largest holdings make up 24% of its $72.7B portfolio in Q2 2025.
- Lazard Asset Management opened 253 new positions and closed 298 in Q2 2025.
- Lazard Asset Management's portfolio value rose 12% quarter-over-quarter to $72.7B.
Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.